PreveCeutical Medical Inc.: A Major Funding Boost through Private Placement
Vancouver, BC – In an exciting development for PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H), the company has announced an increase in the size of its non-brokered private placement, originally set at CA$500,000, to a total of CA$700,000. This move will result in up to 23,333,333 Units being offered at a price of CA$0.03 per Unit.
Company’s Perspective
The private placement, which was increased due to strong investor demand, will provide PreveCeutical with the necessary capital to further its research and development efforts. Each Unit consists of one common share and one-half of one Share purchase warrant. This is an excellent opportunity for investors to join the Company’s mission to develop plant-derived pharmaceuticals and natural health products using its proprietary PrevCanBio™ and PrevCanEx™ technologies.
Investor Impact
For investors, this private placement announcement represents a significant opportunity to invest in a company that is making strides in the pharmaceutical sector. PreveCeutical’s commitment to developing plant-derived pharmaceuticals and natural health products using innovative technologies positions it well for potential growth and success.
Global Implications
The success of PreveCeutical’s private placement is a positive sign for the biotech industry as a whole. As companies continue to invest in research and development, we can expect to see new treatments and therapies emerge, leading to improved health outcomes and quality of life for people around the world.
Conclusion
In summary, PreveCeutical Medical Inc.’s decision to increase the size of its private placement from CA$500,000 to CA$700,000 is an exciting development for the company and its investors. With strong investor demand driving this expansion, PreveCeutical will be able to further its research and development efforts, bringing plant-derived pharmaceuticals and natural health products to market using its proprietary technologies. This not only benefits the company and its investors but also has positive implications for the biotech industry and the global community as a whole.
- PreveCeutical Medical Inc. increases private placement size from CA$500,000 to CA$700,000
- Strong investor demand drives the expansion
- Each Unit consists of one common share and one-half of one Share purchase warrant
- Funding will support research and development efforts
- Positive implications for the biotech industry and the global community
